Evidence map›Paper›PMID 39738540›Full record

ArticleScientific reports2024

HDAC3 inhibitors induce drug resistance by promoting IL-17 A production by T cells.

Hao Chen, Anqi Qin, Fan Xu, Shuai Guo, Ge Zhang, Aihong Zhang, WenTing Li, Feng Tian, Quanhui Zheng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hao ChenHebei Key Laboratory for Chronic Diseases, Tangshan Key Laboratory for Preclinical and Basic Research on Chronic Diseases, School of Basic Medical Sciences, North China University of Science and Technology, Tangshan, 063210, China.
Anqi QinHebei Key Laboratory for Chronic Diseases, Tangshan Key Laboratory for Preclinical and Basic Research on Chronic Diseases, School of Basic Medical Sciences, North China University of Science and Technology, Tangshan, 063210, China.
Fan XuHebei Key Laboratory for Chronic Diseases, Tangshan Key Laboratory for Preclinical and Basic Research on Chronic Diseases, School of Basic Medical Sciences, North China University of Science and Technology, Tangshan, 063210, China.
Shuai GuoHebei Key Laboratory for Chronic Diseases, Tangshan Key Laboratory for Preclinical and Basic Research on Chronic Diseases, School of Basic Medical Sciences, North China University of Science and Technology, Tangshan, 063210, China.
Ge ZhangSchool of Basic Medical, Xingtai Medical College, Xingtai, 054000, China.
Aihong ZhangDepartment of ICU, The Affiliated Hospital of North China University of Science and Technology, Tangshan, 063000, China.
WenTing LiDepartment of Laboratory Animal Science, Health Science Center, Peking University, Beijing, 100083, China.
Feng TianDepartment of Laboratory Animal Science, Health Science Center, Peking University, Beijing, 100083, China.
Quanhui ZhengHebei Key Laboratory for Chronic Diseases, Tangshan Key Laboratory for Preclinical and Basic Research on Chronic Diseases, School of Basic Medical Sciences, North China University of Science and Technology, Tangshan, 063210, China. 1078209929@qq.com.

Funding

Hebei Provincial Health Commission 20190105National Natural Science Foundation of China 8137311
6 · The paper itself

Abstract

HDAC3 has been demonstrated to play a crucial role in the progression of various tumors and the differentiation and development of T cells. However, its impact on peripheral T cells in the development of murine lung cancer remains unclear. In this experiment, a subcutaneous lung tumor model was established in C57BL/6 mice, and tumor-bearing mice were treated with the specific inhibitor of HDAC3, RGFP966, at different doses to observe changes in tumor size. Additionally, a lung tumor model was established using hdac3

Indexed as

CD8-Positive T-LymphocytesHistone Deacetylase InhibitorsHistone DeacetylasesInterleukin-17Lung NeoplasmsMice, Inbred C57BLAcrylamidesAnimalsCell Line, TumorDrug Resistance, NeoplasmGranzymesHistone Deacetylase 3Interferon-gammaMicePhenylenediaminesT-LymphocytesAcrylamidesGranzymesHistone Deacetylase 3Histone Deacetylase InhibitorsHistone DeacetylasesIl17a protein, mouseInterferon-gammaInterleukin-17PhenylenediaminesRGFP966

Identifiers

PMID39738540
PMCPMC11685772

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.